

Marta Bonotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8979817/publications.pdf>

Version: 2024-02-01

56
papers

1,159
citations

471509

17
h-index

395702

33
g-index

56
all docs

56
docs citations

56
times ranked

2250
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	3.7	5
2	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. <i>Breast</i> , 2021, 57, 104-112.	2.2	14
3	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	3.7	5
4	Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 550185.	2.8	13
5	Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1672-1677.	2.5	17
6	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	2.4	1
7	The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1268-1273.	1.0	6
8	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , 2020, 16, 2059-2073.	2.4	2
9	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , 2020, 10, 7010.	3.3	18
10	Abstract P5-14-08: Predictors of relative dose intensity and early dose reduction in patients with metastatic breast cancer treated with palbociclib and endocrine therapy. , 2020, , .		0
11	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019, 11, 1243.	3.7	40
12	The <sc>IMPACT</sc> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 368-377.	7.3	61
13	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12507-e12507.	1.6	2
14	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018, 40, 45-52.	2.2	4
15	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018, 38, 86-91.	2.2	27
16	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 205-213.	2.4	8
17	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13079-e13079.	1.6	2
18	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24014-e24014.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 12039-12039.	1.6	0
20	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opinion on Biological Therapy, 2017, 17, 365-374.	3.1	27
21	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	3.1	85
22	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	3.1	33
23	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treatment Reviews, 2017, 61, 15-22.	7.7	43
24	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Breast, 2017, 31, 114-120.	2.2	49
25	Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. Future Oncology, 2017, 13, 135-144.	2.4	9
26	Molecular classifications of gastric cancers: Novel insights and possible future applications. World Journal of Gastrointestinal Oncology, 2017, 9, 194.	2.0	46
27	Setting and timing of end-of-life care in cancer patients.. Journal of Clinical Oncology, 2017, 35, e21502-e21502.	1.6	0
28	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. Journal of Clinical Oncology, 2017, 35, e12010-e12010.	1.6	0
29	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyâ€™Physicians inform oncological patients.. Journal of Clinical Oncology, 2017, 35, e21632-e21632.	1.6	0
30	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. Oncotarget, 2017, 8, 112816-112824.	1.8	3
31	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. British Journal of Cancer, 2016, 115, 1471-1478.	6.4	45
32	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. Clinical Colorectal Cancer, 2016, 15, 7-15.	2.3	3
33	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. Translational Cancer Research, 2016, 5, S765-S771.	1.0	2
34	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget, 2015, 6, 28716-28730.	1.8	14
35	Looking for predictive markers in breast cancer. Lancet Oncology, The, 2015, 16, e1.	10.7	7
36	Pattern of metastasis and outcome in patients with breast cancer. Clinical and Experimental Metastasis, 2015, 32, 125-133.	3.3	144

#	ARTICLE	IF	CITATIONS
37	The distinctive molecular, pathological and clinical characteristics of <i>BRAF</i> -mutant colorectal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 979-987.	3.1	14
38	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 165-178.	4.4	26
39	Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. <i>Oncologist</i> , 2015, 20, 719-724.	3.7	46
40	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1185-1198.	4.1	4
41	Endocrine maintenance therapy in luminal breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11578-e11578.	1.6	0
42	Treatment during the last month of life in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17649-e17649.	1.6	0
43	Endocrine therapy and chemotherapy in luminal metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11573-e11573.	1.6	0
44	Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. <i>Oncologist</i> , 2014, 19, 608-615.	3.7	205
45	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 925-942.	4.1	32
46	Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12532-e12532.	1.6	9
47	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. <i>Current Drug Targets</i> , 2014, 15, 1225-1230.	2.1	7
48	Differences in hormonal receptor status and Ki67 expression between primary breast cancer and metastasis: Is variation related to previous therapy?. <i>Journal of Clinical Oncology</i> , 2014, 32, e22006-e22006.	1.6	0
49	Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic treatment?. <i>Journal of Clinical Oncology</i> , 2014, 32, e11524-e11524.	1.6	0
50	Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. <i>Drugs</i> , 2013, 73, 2003-2015.	10.9	48
51	Making Capecitabine Targeted Therapy for Breast Cancer: Which is the Role of Thymidine Phosphorylase?. <i>Clinical Breast Cancer</i> , 2013, 13, 167-172.	2.4	22
52	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 8474.	3.3	9
53	Endocrine therapy in patients with metastatic breast cancers (MBC): Prognosis and measures of outcome.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13070-e13070.	1.6	0
54	Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e13058-e13058.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Association of body mass index and outcome in advanced breast cancer.. Journal of Clinical Oncology, 2012, 30, 1044-1044.	1.6	0
56	Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?. Frontiers in Oncology, 0, 12, .	2.8	1